Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BYON4228 in advanced solid tumors
NCT06932952Phase 1Active, not recruiting
- Sponsor
- Byondis
- Start
- May 2025
- Primary completion
- Apr 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of BYON4228 in solid tumor, sponsored by Byondis. Primary endpoints: Dose-Limiting Toxicities at 21 days and Objective Response Rate at 2 years. Started May 2025; status: active, not recruiting.
02
Drugs
BYON4228
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06932952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06932952.